AMA Medical Builds $32M Barbados Drug Factory

A Nigerian manufacturer's $32 million agreement with Nigeria, Barbados and Afreximbank would open a pharmaceutical plant in the Caribbean.

Updated on Nov. 17, 2026 in Healthcare

Bold flat-color editorial illustration of a clear intravenous fluid bag on a steel stand beside a shipping container, in deep red, cream, and teal, reflecting cross-border drug manufacturing.
AMA Medical Manufacturing secured a $32 million agreement with Nigeria, Barbados and Afreximbank to build an IV-fluid pharmaceutical plant in Barbados by 2029. AI Illustration. Upload story photo >

Live Poll

Do you think medicine prices in Nigeria will get better or worse in the next few years?

AMA Medical Manufacturing has secured a $32 million agreement involving Nigeria, Barbados and the African Export-Import Bank to build a pharmaceutical factory in Barbados. Samuel Adeoye, Vice President of Partnerships at Pan-African, disclosed the deal in a LinkedIn post.

Why it matters

More than 70 per cent of medicines consumed in Nigeria are sourced from abroad, highlighting the country's reliance on imported pharmaceuticals. The project reflects efforts to expand drug manufacturing capacity beyond Africa, with development financing supporting the venture.

The proposed facility would produce intravenous fluids at an annual capacity of 12 million units under a $32 million agreement. Details on construction milestones, final financing structure and approvals were not disclosed.

The players

AMA Medical Manufacturing

A Nigerian pharmaceutical manufacturer pursuing international production expansion through the proposed Barbados facility.

African Export-Import Bank (Afreximbank)

A Pan-African multilateral financial institution that provides trade and development financing across African markets, including pharmaceutical projects.

The details

The proposed Barbados facility will manufacture intravenous (IV) fluids and is expected to begin production in 2029, adding to AMA Medical Manufacturing's international manufacturing footprint. The agreement includes development financing supporting pharmaceutical production capacity outside Africa.

Timeline

  1. 2029: Expected start of production at the Caribbean factory.

  2. Nov. 17, 2026: Date of the article reporting the agreement and Nigeria's import dependence.

Market Landscape

The deal reflects a pattern of African firms and development lenders seeking to build pharmaceutical capacity to reduce import dependence. Placing production in the Caribbean rather than Africa signals how Nigerian manufacturers are pursuing international footprints in the regional drug supply market.

For patients in Nigeria, the project points toward a future where more of the medicines they depend on could be produced domestically or regionally rather than imported. Near-term consumer effects on drug availability or pricing are not addressed in the source.

The takeaway

Pharmaceutical supply chains are diversifying, and African financing is increasingly backing manufacturing outside the continent. Watch for construction progress and financing details as the 2029 production target approaches.

Further reading

For broader context on pharmaceutical supply and manufacturing, explore Healthcare coverage.

Live Poll

Do you think medicine prices in Nigeria will get better or worse in the next few years?